Adarx Pharmaceuticals Inc ADRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $17.13
- Day Range
- $17.18–17.88
- 52-Week Range
- $16.61–23.21
- Bid/Ask
- $17.39 / $17.55
- Shares Outstanding
- 106.80M
- Market Cap
- $1.86B
- Volume/Avg
- 93,620 / 859,795
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 210.65
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.adarx.com
Valuation
|
Metric
|
ADRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 210.65 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ADRX
|
|---|---|
Quick Ratio | 12.56 |
Current Ratio | 12.98 |
Interest Coverage | — |
Quick Ratio
ADRX
Profitability
|
Metric
|
ADRX
|
|---|---|
Return on Assets (Normalized) | −17.06% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ADRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&>!$Br@ | LOCK|!<#p> | $133B | |||
| Moderna Inc
MRNA
| LOCK|x^y$!M | LOCK|#% | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&zCYl! | LOCK|@xkB | $83B | |||
| argenx SE ADR
ARGX
| LOCK|^yb$V! | LOCK|^Q# | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|H#MyRNn | LOCK|jF | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?HgHFf# | LOCK|WJ>v | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|lF$n&%pt | LOCK|@Db& | $28B | |||
| Incyte Corp
INCY
| LOCK|!tB%?P | LOCK|R?d | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|r#p<B^t | LOCK|g> | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!#Njb$! | LOCK|QG | $14B |
United States